oral covalent BTK inhibitor
>80% BTK occupancy <5 mg (Ph. I dose esc.)
from fragment-based screen of 11k cmpds
Journal of Medicinal Chemistry
Takeda, San Diego, CA, USA
TAK-020
The Takeda covalent BTK inhibitor clinical candidate, TAK-020, is a highly selective oral covalent BTK inhibitor with safety and tolerability profiles that are promising for both hematologic malignancies and autoimmune…